Abstract
Data on survival of BRCA1/2-associated primary breast cancer (PBC) patients who opt for subsequent contralateral risk-reducing mastectomy (CRRM) are scarce and inconsistent. We examined the efficacy of CRRM on overall survival in mutation carriers with a history of PBC. From a Dutch multicentre cohort, we selected 583 BRCA-associated PBC patients, being diagnosed between 1980 and 2011. Over time, 242 patients (42%) underwent CRRM and 341 patients (58%) remained under surveillance. Survival analyses were performed using Cox models, with CRRM as a time-dependent covariate. The median follow-up after PBC diagnosis was 11.4 years. In the CRRM group, four patients developed contralateral breast cancer (2%), against 64 patients (19%) in the surveillance group (p
| Original language | English |
|---|---|
| Pages (from-to) | 668-677 |
| Number of pages | 10 |
| Journal | International Journal of Cancer |
| Volume | 136 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 15 Feb 2015 |
Keywords
- BRCA1
- 2
- breast cancer
- prevention
- contralateral risk-reducing mastectomy
- survival
Fingerprint
Dive into the research topics of 'Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver